<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667494</url>
  </required_header>
  <id_info>
    <org_study_id>2020P003179</org_study_id>
    <nct_id>NCT04667494</nct_id>
  </id_info>
  <brief_title>Ultrasound Therapy In Cardiac Amyloidosis</brief_title>
  <acronym>UTICA</acronym>
  <official_title>Ultrasound Therapy In Cardiac Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective pilot clinical study of subjects with cardiac amyloidosis and control&#xD;
      subjects without amyloidosis where we plan to evaluate changes in myocardial blood flow,&#xD;
      systolic and diastolic function before and after sonotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      70 subjects will be enrolled in this study in 3 study groups: A) 30 subjects with light chain&#xD;
      cardiac amyloidosis B) 30 subjects with transthyretin cardiac amyloidosis and C) 10 subjects&#xD;
      without amyloidosis. All subjects will undergo rest 2D echocardiography, rest N-13 ammonia&#xD;
      perfusion PET, Definity infusion with high mechanical index (MI) imaging defined as&#xD;
      sonotherapy in this study protocol.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Outcome measures will be evaluated before and after intervention with sonotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial Blood Flow</measure>
    <time_frame>1 day</time_frame>
    <description>N-13 ammonia PET based measure of myocardial blood flow in ml/gm/min</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic Function</measure>
    <time_frame>1 day</time_frame>
    <description>Global Longitudinal Strain by echocardiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic Function</measure>
    <time_frame>1 day</time_frame>
    <description>Echo measured mitral e' velocity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Amyloidosis Cardiac</condition>
  <arm_group>
    <arm_group_label>Sonotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will undergo sonotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Sonotherapy</intervention_name>
    <description>Use of high mechanical index ultrasound therapy with intravenous Definity contrast infusion</description>
    <arm_group_label>Sonotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years for AL-CA, &gt; 65 years for ATTR-CA, &gt; 65 years for controls&#xD;
&#xD;
          -  Willing and able to provide consent&#xD;
&#xD;
          -  Diagnosis of systemic light chain amyloidosis by standard criteria (see below) and in&#xD;
             hematological remission (normal serum free light chain levels)&#xD;
&#xD;
               -  (immunofixation of serum and urine, IgG free light chain (FLC) assay, a biopsy of&#xD;
                  fat pad/ bone marrow, or organ biopsy, followed by typing of the light chain&#xD;
                  using immunohistochemistry or immunogold assay with confirmation by Mass&#xD;
                  spectroscopy as needed) AND&#xD;
&#xD;
               -  proof of cardiac involvement by AL amyloidosis&#xD;
&#xD;
               -  abnormal cardiac biomarkers (Abnormal high sensitivity TnT 5th generation levels&#xD;
                  (&gt;9 ng/L: female, &gt;14 ng/L: male) or abnormal age appropriate N terminal&#xD;
                  pro-brain natriuretic peptide, NT-proBNP (abnormal values: &lt;50 years: &gt;450 pg/ml;&#xD;
                  50-75 years:&gt;900 pg/ml; &gt;75 years: &gt;1800 pg/ml) or&#xD;
&#xD;
               -  abnormal echocardiogram (wall thickness &gt; 12 mm) or&#xD;
&#xD;
               -  abnormal cardiac MRI (wall thickness &gt; 12 mm or extracellular volume &gt; 0.35) OR&#xD;
&#xD;
          -  Diagnosis of transthyretin cardiac amyloidosis by standard criteria&#xD;
&#xD;
               -  endomyocardial biopsy followed by typing of the transthyretin amyloidosis using&#xD;
                  immunohistochemistry or immunogold assay with confirmation by Mass spectroscopy&#xD;
                  as needed&#xD;
&#xD;
               -  extracardiac biopsy with typical cardiac imaging findings, or&#xD;
&#xD;
               -  grade 2 or grade 3 myocardial uptake of technetium-99m pyrophosphate (PYP) if AL&#xD;
                  amyloidosis is excluded&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  Severe claustrophobia despite use of sedatives&#xD;
&#xD;
          -  Decompensated heart failure (unable to lie flat for 1 hour)&#xD;
&#xD;
          -  Concomitant non-ischemic non-amyloid heart disease (valvular heart disease or dilated&#xD;
             cardiomyopathy)&#xD;
&#xD;
          -  Severe valve stenosis or regurgitation in the aortic, mitral or tricuspid valves,&#xD;
             including prior valve replacement&#xD;
&#xD;
          -  Severe pulmonary artery hypertension&#xD;
&#xD;
          -  Severe lung disease&#xD;
&#xD;
          -  Known obstructive epicardial coronary artery disease with stenosis &gt; 50% in any single&#xD;
             territory&#xD;
&#xD;
          -  Prior cardiac surgery&#xD;
&#xD;
          -  Regional wall motion abnormality on echocardiogram&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 40%&#xD;
&#xD;
          -  Pregnant state&#xD;
&#xD;
          -  Documented allergy to N-13 ammonia or Definity&#xD;
&#xD;
          -  Contraindications to CMR&#xD;
&#xD;
               -  Implantable Cardioverter Defibrillator (ICD)&#xD;
&#xD;
               -  Significant renal dysfunction with estimated glomerular filtration rate &lt; 30&#xD;
                  ml/min/m2.&#xD;
&#xD;
               -  Dialysis&#xD;
&#xD;
          -  Contraindications to DEFINITYÂ® (Perflutren Lipid Microsphere) Injectable Suspension:&#xD;
&#xD;
             o Patients with known or suspected Right-to-left, bi-directional, or transient&#xD;
             right-to-left cardiac shunts, Hypersensitivity to perflutren&#xD;
&#xD;
          -  Contraindications or challenges to sonotherapy&#xD;
&#xD;
               -  Severe electrolyte abnormalities&#xD;
&#xD;
               -  QTc prolongation (values are greater than 450 milliseconds in males and greater&#xD;
                  than 470 milliseconds in females)&#xD;
&#xD;
               -  BMI &gt; 35 kg/m2&#xD;
&#xD;
               -  Documented intracardiac thrombus&#xD;
&#xD;
               -  Atrial fibrillation not on anticoagulation&#xD;
&#xD;
               -  Prior history of stroke&#xD;
&#xD;
          -  Any other reason determined by the investigator that makes a subject a poor candidate&#xD;
             for ultrasound therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sharmila Dorbala, MD</last_name>
    <phone>617-732-6290</phone>
    <email>sdorbala@bwh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah M Cuddy, MD</last_name>
    <phone>617-278-0444</phone>
    <email>scuddy1@bwh.harvard.edu</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Sharmila Dorbala</investigator_full_name>
    <investigator_title>Director, Nuclear Cardiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IRD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

